Delaware federal district court rules in favor of acadia pharmaceuticals in nuplazid® (pimavanserin) patent litigation

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the u.s. district court for the district of delaware has granted summary judgment to acadia, confirming validity of the nuplazid® (pimavanserin) '740 composition of matter patent. the court ruled in favor of acadia on all grounds. the ruling came in acadia's litigation against msn laboratories pvt. ltd., msn pharmaceuticals, inc. and other anda (abbreviated new drug application) filers and concludes this.
ACAD Ratings Summary
ACAD Quant Ranking